This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will RedHill Biopharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor RedHill Biopharma
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
by Zacks Equity Research
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
Actinium Treats First Patient in AML Study on Actimab-A Combo
by Zacks Equity Research
Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.
Zacks Market Edge Highlights: Boot Barn, Alteryx, RedHill Biopharma, Innovative Industrial Properties and SPS Commerce
by Zacks Equity Research
Zacks Market Edge Highlights: Boot Barn, Alteryx, RedHill Biopharma, Innovative Industrial Properties and SPS Commerce
How to Screen for the Best Growth Stocks
by Tracey Ryniec
Wouldn't you like a list of the top growth stocks right now?
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
by Zacks Equity Research
The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.
IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts IntelGenx's (IGXT) NDA resubmssion for its migraine candidate Rizaport 10 mg. The stock appreciates.
High Fiber Solutions Revenues to Aid Zayo (ZAYO) Q4 Earnings
by Zacks Equity Research
Strong momentum in Fiber Solutions business and solid inorganic growth are likely to drive Zayo's (ZAYO) fiscal Q4 revenues although margin woes remain a concern.
What's in the Offing for Keysight (KEYS) in Q3 Earnings?
by Zacks Equity Research
Keysight's (KEYS) focus on launching new solutions for growth markets like 5G, IoT, next-generation wireless, high-speed datacenters and automotive & energy bodes well for its top-line.
What's in the Offing for Pure Storage (PSTG) in Q2 Earnings?
by Zacks Equity Research
Pure Storage (PSTG) is rapidly gaining traction in the flash storage market, which is evident from its expanding customer base.
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
by Zacks Equity Research
Small drugmakers, in general, are having a rather poor year, the principle reason being failure of key pipeline candidates in pivotal studies.
RedHill Gets Two New Patents for Crohn's Disease Candidate
by Zacks Equity Research
RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.
RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
RedHill Biopharma (RDHL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
RedHill Biopharma (RDHL): Moving Average Crossover Alert
by Zacks Equity Research
RedHill Biopharma Ltd. (RDHL) is looking like an interesting pick from a technical perspective
Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.
RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher
by Zacks Equity Research
RedHill Biopharma (RDHL) was a big mover last session, as the company saw its shares rise more than 10% on the day.
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
by Zacks Equity Research
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
5 Stocks in Focus on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Company News for April 05, 2017
by Zacks Equity Research
Company News for April 05, 2017
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
by Arpita Dutt
The Q4 earnings season has started on a good note with both earnings and revenue growth improving compared to recent quarters.